CA3133117C - A delivery system comprising silicon nanoparticles - Google Patents

A delivery system comprising silicon nanoparticles Download PDF

Info

Publication number
CA3133117C
CA3133117C CA3133117A CA3133117A CA3133117C CA 3133117 C CA3133117 C CA 3133117C CA 3133117 A CA3133117 A CA 3133117A CA 3133117 A CA3133117 A CA 3133117A CA 3133117 C CA3133117 C CA 3133117C
Authority
CA
Canada
Prior art keywords
silicon
sirna
lipid
nanoparticles
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3133117A
Other languages
English (en)
French (fr)
Other versions
CA3133117A1 (en
Inventor
Roghieh Suzanne SAFFIE-SIEBERT
Paulina Malgorzata BARAN-RACHWALSKA
Flavia Maria SUTERA
Nasrollah TORABI-POUR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sisaf Ltd
Original Assignee
Sisaf Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sisaf Ltd filed Critical Sisaf Ltd
Publication of CA3133117A1 publication Critical patent/CA3133117A1/en
Application granted granted Critical
Publication of CA3133117C publication Critical patent/CA3133117C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
CA3133117A 2019-03-28 2020-03-30 A delivery system comprising silicon nanoparticles Active CA3133117C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1904337.1 2019-03-28
GBGB1904337.1A GB201904337D0 (en) 2019-03-28 2019-03-28 A delivery system
PCT/GB2020/050854 WO2020193999A1 (en) 2019-03-28 2020-03-30 A delivery system comprising silicon nanoparticles

Publications (2)

Publication Number Publication Date
CA3133117A1 CA3133117A1 (en) 2020-10-01
CA3133117C true CA3133117C (en) 2024-04-02

Family

ID=66442849

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3133117A Active CA3133117C (en) 2019-03-28 2020-03-30 A delivery system comprising silicon nanoparticles

Country Status (8)

Country Link
US (2) US12496278B2 (https=)
EP (1) EP3946280A1 (https=)
JP (2) JP7637416B2 (https=)
CN (2) CN117398362A (https=)
AU (1) AU2020249810B2 (https=)
CA (1) CA3133117C (https=)
GB (1) GB201904337D0 (https=)
WO (1) WO2020193999A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022132196A (ja) * 2021-02-26 2022-09-07 ナノ ターゲティング アンド セラピー バイオファーマ インコーポレイテッド 薬剤を後眼部に送達するための方法およびその使用
GB202110645D0 (en) * 2021-07-23 2021-09-08 Sisaf Ltd Protection of biological molecules from degradation
GB202110644D0 (en) * 2021-07-23 2021-09-08 Sisaf Ltd Improved nucleic acid vector particles
GB202110646D0 (en) * 2021-07-23 2021-09-08 Sisaf Ltd Nucleic acid vector compositions
CN121622565A (zh) * 2022-05-16 2026-03-10 苏州维益生物科技有限公司 纳米颗粒、其制备和应用、及包括其的眼疾药物及其制备
GB202210794D0 (en) 2022-07-22 2022-09-07 Sisaf Ltd Lipid formulations
GB202300914D0 (en) * 2023-01-20 2023-03-08 Sisaf Ltd Manufacturing process
GB202300915D0 (en) * 2023-01-20 2023-03-08 Sisaf Ltd mRNA COMPOSITIONS
GB202300911D0 (en) * 2023-01-20 2023-03-08 Sisaf Ltd Therapeutic compositions and methods
GB202300912D0 (en) * 2023-01-20 2023-03-08 Sisaf Ltd Therapeutic compostions and methods
CN116473928B (zh) * 2023-03-01 2024-06-14 东北师范大学 精氨酸/磷酸钙纳米粒子的制备方法及其应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK175531B1 (da) 1986-12-15 2004-11-22 Nexstar Pharmaceuticals Inc Leveringsvehikel med amphiphil-associeret aktiv bestanddel
NL9400189A (nl) 1994-02-07 1995-09-01 Bio Pharma Sciences Bv Gestabiliseerd orthosiliciumzuur bevattend preparaat, een werkwijze voor het bereiden daarvan en een biologisch preparaat.
CN1227482A (zh) 1996-06-27 1999-09-01 普罗克特和甘保尔公司 化妆品组合物
FR2799758B1 (fr) 1999-10-15 2002-05-17 Exsymol Sa Complexe a base d'acide orthosilicique biologiquement assimilable, se presentant sous forme solide, stable et concentree, et procede de preparation
GB0104383D0 (en) 2001-02-22 2001-04-11 Psimedica Ltd Cancer Treatment
US6670335B2 (en) 2001-03-05 2003-12-30 A. P. Pharma, Inc. Fluorouracil-containing formulation
EP1391426A1 (en) 2002-08-12 2004-02-25 Bio Minerals N.V. Method for the preparation of a silicic acid comprising extrudate, said extrudate, its use and a pharmaceutical composition comprising the said extrudate
JP2006016390A (ja) 2004-06-04 2006-01-19 Toyo Shinyaku:Kk プロアントシアニジン含有組成物
CN1981044B (zh) * 2004-06-07 2010-05-05 普洛体维生物治疗公司 包封干扰rna的脂质
ES2669585T3 (es) 2004-10-29 2018-05-28 The Regents Of The University Of California Micropartículas porosas de silicio para la entrega de fármaco para el ojo
CN101277704A (zh) * 2005-04-12 2008-10-01 因特拉迪格姆公司 用于治疗癌症及其它新血管生成疾病的RNAi治疗剂的组合物和方法
GB0515353D0 (en) 2005-07-27 2005-08-31 Psimedica Ltd Food
US8920821B2 (en) 2006-04-14 2014-12-30 Perrigo Israel Pharmaceuticals Ltd. Pharmaceutical compositions comprising silica microspheres
US7696866B2 (en) 2007-06-28 2010-04-13 Microsoft Corporation Learning and reasoning about the context-sensitive reliability of sensors
KR20160021307A (ko) * 2007-07-10 2016-02-24 더 리전트 오브 더 유니버시티 오브 캘리포니아 선택된 조직에 조성물을 전달하는 물질 및 방법
US20090053268A1 (en) 2007-08-22 2009-02-26 Depablo Juan J Nanoparticle modified lubricants and waxes with enhanced properties
EP2030632A1 (en) 2007-09-03 2009-03-04 UMC Utrecht Holding B.V. A carrier particle for use in bio-applications
GB0817936D0 (en) 2008-09-30 2008-11-05 Intrinsiq Materials Global Ltd Porous materials
IT1394656B1 (it) 2009-07-03 2012-07-05 Brev Angela Srl Processo per la produzione e l'assemblaggio di una siringa per operazioni medicali
GB0913255D0 (en) 2009-07-30 2009-09-02 Sisaf Ltd Topical composition
JP2011032194A (ja) 2009-07-31 2011-02-17 Kracie Home Products Ltd 油中水型乳化化粧料
US8992984B1 (en) 2009-10-21 2015-03-31 Stc.Unm Protocells and their use for targeted delivery of multicomponent cargos to cancer cells
ES2385080B1 (es) * 2010-12-21 2013-05-10 Universidad Del Pais Vasco-Euskal Herriko Unibertsitatea Nanopartículas lipídicas para el tratamiento de enfermedades oculares.
EP2765997A4 (en) 2011-10-14 2015-06-24 Stc Unm POROUS NANOPARTICLE-SUPPORTED LIPID DOUBLE LAYERS (PROTOCOLS) FOR THE TARGETED RELEASE BY TRANSDERMAL RELEASE AND USE METHOD THEREFOR
US9096679B2 (en) * 2012-12-03 2015-08-04 The Board Of Regents Of The University Of Oklahoma Peptide compounds and methods of production and use thereof
EP2968571A4 (en) 2013-03-15 2016-09-07 Psivida Inc BIODEGRADABLE SILICONE BASED COMPOSITIONS FOR THE DELIVERY OF THERAPEUTIC AGENTS
US20170165375A1 (en) 2013-04-02 2017-06-15 Stc. Unm Antibiotic protocells and related pharmaceutical formulations and methods of treatment
JP2016521568A (ja) 2013-06-12 2016-07-25 ユニヴェルシテ・ドゥ・ナミュールＵｎｉｖｅｒｓｉｔｅ ｄｅ Ｎａｍｕｒ 生細胞の冷凍保存
EP3470089A1 (en) * 2013-12-12 2019-04-17 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
GB201402669D0 (en) 2014-02-14 2014-04-02 Medical Res Council Stabilised silicate compositions and their uses
EP2946793A1 (en) * 2014-05-23 2015-11-25 Universitat Rovira I Virgili Silicon particles targeting tumor cells
CN104127886A (zh) 2014-07-16 2014-11-05 上海理工大学 一种CpG核酸药物输送系统及其制备方法
CN105434205A (zh) 2014-11-08 2016-03-30 马南行 一种眼部快速弹开皱纹延缓衰老的组合物及其制备方法
CN114533898B (zh) * 2015-07-09 2025-07-01 加利福尼亚大学董事会 融合脂质体包被的多孔硅纳米颗粒
LU92784B1 (en) 2015-07-22 2017-01-31 Luxembourg Inst Of Science And Tech (List) Negatively charged self-assembling supported lipid bilayer on mesoporous silica nanoparticles, method of synthesis and use as a nanovector
WO2017040976A1 (en) * 2015-09-02 2017-03-09 Erkki Ruoslahti Compounds and compositions for targeting brain injuries and methods of use thereof
US20180344641A1 (en) 2015-09-04 2018-12-06 C. Jeffrey Brinker Mesoporous silica nanoparticles and supported lipid bi-layer nanoparticles for biomedical applications
US20190262469A1 (en) 2015-09-04 2019-08-29 C. Jeffrey Brinker Protocells to treat microbial infection and for synergistic delivery
JP7384512B2 (ja) * 2015-10-22 2023-11-21 モデルナティエックス インコーポレイテッド 広域インフルエンザウイルスワクチン
EP4218739A3 (en) 2016-01-08 2023-08-09 The Regents of The University of California Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery
WO2017181115A1 (en) * 2016-04-14 2017-10-19 Spinnaker Biosciences, Inc. Porous silicon materials comprising a metal silicate for delivery of therapeutic agents
CN106177982A (zh) 2016-07-26 2016-12-07 上海应用技术学院 一种透明质酸修饰的脂质介孔硅核壳纳米组装体及其制备方法
JP7510254B2 (ja) 2016-08-10 2024-07-03 ユナイテッド キングダム リサーチ アンド イノベーション ナノシリカ粒子を含む組成物および療法のためにｔリンパ球を活性化する方法におけるそれらの使用
CN106265432A (zh) 2016-08-30 2017-01-04 钟治超 一种含有薄荷精油的美白美容乳剂
LU100023B1 (en) 2017-01-20 2018-07-30 Luxembourg Inst Science & Tech List Nanocapsules and method for manufacturing thereof
CN106806343B (zh) 2017-02-17 2020-10-13 清华大学深圳研究生院 一种叶酸和聚多巴胺修饰的肿瘤靶向介孔二氧化硅纳米粒及制备方法与应用
US20200261580A1 (en) 2017-07-17 2020-08-20 Andrea Willey Photodynamic Therapy Method for Skin Disorders
US20200375912A1 (en) 2017-08-03 2020-12-03 Rita Elena Serda Liposomal coated nanoparticles for immunotherapy applications
CN107625966A (zh) 2017-09-10 2018-01-26 河南工业大学 一种自组装式脂质‑介孔硅核/壳复合型纳米药物载体及其制备方法
CN107616952A (zh) 2017-10-31 2018-01-23 广州赛莱拉干细胞科技股份有限公司 一种含菊花细胞提取物的祛皱护肤组合物及其制备方法
CN107998264A (zh) 2018-01-15 2018-05-08 福建傲农生物科技集团股份有限公司 一种治疗猪呼吸道疾病的中西药复方超微粉剂及其制备方法与应用
CN108552223A (zh) 2018-01-17 2018-09-21 天津市植物保护研究所 一种含芽胞杆菌的液体菌悬剂及其应用

Also Published As

Publication number Publication date
US20260096997A1 (en) 2026-04-09
CN113677332B (zh) 2023-11-03
AU2020249810B2 (en) 2024-12-19
JP2024169482A (ja) 2024-12-05
JP2022529579A (ja) 2022-06-23
AU2020249810A1 (en) 2021-11-11
EP3946280A1 (en) 2022-02-09
US20230052784A1 (en) 2023-02-16
CN117398362A (zh) 2024-01-16
US12496278B2 (en) 2025-12-16
JP7784754B2 (ja) 2025-12-12
GB201904337D0 (en) 2019-05-15
JP7637416B2 (ja) 2025-02-28
CN113677332A (zh) 2021-11-19
WO2020193999A1 (en) 2020-10-01
CA3133117A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
CA3133117C (en) A delivery system comprising silicon nanoparticles
Lu et al. Novel hyaluronic acid–chitosan nanoparticles as non-viral gene delivery vectors targeting osteoarthritis
US8936907B2 (en) Neural transfection reagents
Baran-Rachwalska et al. Topical siRNA delivery to the cornea and anterior eye by hybrid silicon-lipid nanoparticles
ES2362376T3 (es) Nanopartículas para la administración de ácido nucleico.
Srinivasan et al. Optimization and characterization of anionic lipoplexes for gene delivery
ES2734974T3 (es) Nanopartículas lipídicas para el tratamiento de enfermedades oculares
Foged siRNA delivery with lipid-based systems: promises and pitfalls
US20240327870A1 (en) Nucleic acid vector compositions
Supe et al. Liposome-polyethylenimine complexes for the effective delivery of HuR siRNA in the treatment of diabetic retinopathy
US20170072064A1 (en) Highly stable biodegradable gene vector platforms for overcoming biological barriers
JP2024527441A (ja) ドープシリコン粒子を含む組成物、及び関連する方法
CN101646443B (zh) 速效型核酸转运用载体组合物
Khar et al. Nano-vectors for the ocular delivery of nucleic acid-based therapeutics
WO2020070524A1 (en) Lipidic drug carriers for cell and organ delivery
WO2023165583A1 (zh) 靶向眼部细胞的递送系统和方法
Pérez et al. Formulation Strategies, Characterization, and In Vitro Evaluation of Lecithin‐Based Nanoparticles for siRNA Delivery
González Sebastián Ezequiel Pérez, Yamila Gándola, Adriana Mónica Carlucci &
Niculescu et al. New applications of lipid and polymer-based nanoparticles for nucleic acids delivery. Pharmaceutics. 2021; 13: 2053
Saarela et al. Bioinspired Virus-Like Porous Silica Amplify Lipid-Mediated mRNA Delivery
Grant-Serroukh Lipid nanoparticles for mRNA-mediated cancer therapy
WO2024182734A2 (en) Low cost efficient intracellular delivery of proteins and nucleic acids via hydrophobic ion pairing
KR20240118489A (ko) 단일 용기를 이용하는 유기 용매를 사용하지 않는 열순환기법에 의한 핵산 전달용 지질나노입자의 제조방법
D’Souza et al. Nanomedicine in nucleic acid therapy
Daniels Elucidation of Gene Function Using RNA Interference in a Cancer Cell Culture Model

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231010

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250227

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250228

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250228

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260323

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260323